Bokf Na Increases Position in Insulet Co. (NASDAQ:PODD)

Bokf Na increased its stake in Insulet Co. (NASDAQ:PODD) by 10.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,703 shares of the medical instruments supplier’s stock after purchasing an additional 1,001 shares during the quarter. Bokf Na’s holdings in Insulet were worth $2,160,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in PODD. International Assets Investment Management LLC purchased a new position in Insulet during the 2nd quarter valued at about $32,000. Sunbelt Securities Inc. purchased a new position in Insulet during the 1st quarter valued at about $29,000. UMB Bank n.a. increased its holdings in Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 81 shares in the last quarter. Jones Financial Companies Lllp purchased a new position in Insulet during the 4th quarter valued at about $40,000. Finally, CVA Family Office LLC increased its holdings in Insulet by 138.1% during the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 145 shares in the last quarter.

Analyst Upgrades and Downgrades

PODD has been the subject of several recent research reports. BTIG Research dropped their target price on shares of Insulet from $270.00 to $250.00 and set a “buy” rating for the company in a report on Friday, August 9th. UBS Group lifted their price target on shares of Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a report on Friday, August 9th. Barclays lifted their price target on shares of Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. OTR Global reiterated a “mixed” rating on shares of Insulet in a report on Monday, June 10th. Finally, Redburn Atlantic started coverage on shares of Insulet in a report on Thursday, May 30th. They set a “buy” rating and a $235.00 price target for the company. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $225.29.

Insulet Price Performance

PODD opened at $233.87 on Friday. The company’s 50 day simple moving average is $199.23 and its 200 day simple moving average is $185.86. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60. Insulet Co. has a 1 year low of $125.82 and a 1 year high of $234.71. The stock has a market capitalization of $16.40 billion, a PE ratio of 70.87, a P/E/G ratio of 4.26 and a beta of 1.21.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). The business had revenue of $488.50 million for the quarter, compared to analyst estimates of $488.00 million. Insulet had a net margin of 21.11% and a return on equity of 30.73%. The company’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period last year, the firm earned $0.38 earnings per share. As a group, sell-side analysts expect that Insulet Co. will post 3.04 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.